Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020
November 06 2020 - 9:26AM
Trading in Novo Nordisk shares by board members, executives and
associated persons on 4 and 5 November 2020
Bagsværd, Denmark,
6 November
2020 — This document discloses
the data of the transaction(s) made in Novo Nordisk shares by the
company’s board members, executives and their associated persons in
accordance with Article 19 of Regulation No. 596/2014 on market
abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Kasim Kutay |
2 |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument, type of instrument,
Identification code |
ADRsNVO |
b) |
Nature of the transaction |
Purchase of ADRs |
c) |
Price(s) and volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
DKK 437.69 |
378 ADRs |
|
|
|
|
|
d) |
Aggregated information
|
378 ADRsDKK 437.69 |
e) |
Date of the transaction |
2020-11-04 |
f) |
Place of the transaction |
New York Stock Exchange |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Stig Strøbæk |
2 |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors(Employee representative) |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument, type of instrument,
Identification code |
SharesNovo Nordisk B DK0060534915 |
b) |
Nature of the transaction |
Sale of shares |
c) |
Price(s) and volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
DKK 449.60 |
400 shares |
|
|
|
|
d) |
Aggregated information
|
400 shares449.60 |
e) |
Date of the transaction |
2020-11-05 |
f) |
Place of the transaction |
Nasdaq Copenhagen |
Definitions and background information:
Publication
Publication shall take place no later than three working days
after the trading by board members, executives or their associated
persons. Publication is only required when the total amount of
transactions of a specific board member/executive or his/her
associated persons in any one calendar year has reached EUR 20,000
(calculated individually).
Who are board members, executives and associated
persons?
Board members and executives are members of the Board of
Directors and Executive Management, respectively, of Novo Nordisk
A/S. Associated persons are defined as the following persons
associated to a board member/executive: 1) spouse or cohabitant, 2)
children under the age of 18 years, 3) Other relatives defined as
brothers, sisters, parents, grandparents, children, grandchildren,
cousins etc. who have shared the same household with a board member
or executive for a period of at least one year on the date of the
given transaction and 4) any legal persons, trust, or partnership,
the managerial responsibilities of which are discharged by a board
member/executive or by a person referred to in items 1)-3) above,
or which is directly or indirectly controlled by such a person, or
which is set up for the benefit of such a person, or the economic
interests of which are substantially equivalent to those of such a
person.
What is trading/transaction?
Trading is any kind of transaction, including shares and share
related securities purchased or otherwise acquired, sold or
otherwise disposed, gifts, mortgages, heritage and grants,
allotments and exercise of options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for
ADRs held in 401(k) retirement plan by US-based employees. The ID
code is the code (ISIN DK0060534915) of the Novo Nordisk share on
the Nasdaq Copenhagen or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, i.e. Nasdaq
Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and
aggregated information?
The volume of transaction is the number of shares (of DKK 0.20
nominal value) or other financial instruments traded. In case of a
single transaction the price is the price of that single
transaction. In case of multiple transactions, when the
transactions relate to the same financial instrument, are of the
same nature, are executed on the same day and are executed on the
same place, the volume must be aggregated. The price of the
aggregated transactions is the weighted average price.
The exchange rate of the Danish Central Bank (Nationalbanken) on
the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 43,100 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 4442
3883 |
mkd@novonordisk.com |
Ken Inchausti
(US) |
+1 609 240
9429 |
kiau@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079
0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079
4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 68
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024